{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:02:45Z","timestamp":1785546165278,"version":"3.56.0"},"reference-count":82,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p> The success in preventing hepatitis B virus and human papillomavirus infections by means of vaccination paves the way for the development of other vaccines to prevent sexually transmitted infections (STIs) such as gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. The current status of vaccine development for these infections will be explored in this review. <\/jats:p><jats:p> The general principles for success include the need for prevention of latency, persistence and repeat infections. A reduction in transmission of STIs would reduce the global burden of disease. Therapeutic activity of vaccines against STIs would be advantageous over preventative activity alone, and prevention of congenital and neonatal infections would be an added benefit. There would be an added value in the prevention of long-term consequences of STIs. It may be possible to re-purpose \u2018old\u2019 vaccines for new indications. One of the major challenges is the determination of the target populations for STI vaccination. <\/jats:p>","DOI":"10.1177\/2515135520923887","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T11:30:26Z","timestamp":1593257426000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus"],"prefix":"10.1177","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-9043","authenticated-orcid":false,"given":"Edwin David G.","family":"McIntosh","sequence":"first","affiliation":[{"name":"FEO - Faculty Education Office (Medicine), Imperial College London, Sir Alexander Fleming Building, South Kensington Campus, London, SW7 2AZ, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,27]]},"reference":[{"key":"bibr1-2515135520923887","unstructured":"World Health Organization. Sexually transmitted infections, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/sexually-transmitted-infections-(stis) (2019). (accessed 14 June 2019)."},{"key":"bibr2-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.081"},{"key":"bibr3-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.053"},{"key":"bibr4-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1086\/652400"},{"key":"bibr5-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.134"},{"key":"bibr6-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.146"},{"key":"bibr7-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14632-14639.2005"},{"key":"bibr8-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/ilar\/ilx032"},{"key":"bibr9-2515135520923887","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QCO.0000000000000343","volume":"30","author":"Gottlieb SL","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"bibr10-2515135520923887","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.228486"},{"key":"bibr11-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02552-19"},{"key":"bibr12-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1071\/SH19060"},{"key":"bibr13-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1061"},{"key":"bibr14-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1381810"},{"key":"bibr15-2515135520923887","unstructured":"Institute of Environmental Science and Research Ltd. Sexually transmitted infections in New Zealand: annual surveillance report 2014. Porirua (New Zealand), https:\/\/surv.esr.cri.nz\/surveillance\/annual_sti.php?we_objectID=4844 (2015). (accessed 9 September 2019)."},{"key":"bibr16-2515135520923887","doi-asserted-by":"publisher","DOI":"10.4161\/hv.36221"},{"key":"bibr17-2515135520923887","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00683"},{"key":"bibr18-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT04094883. Study to assess gonorrhoeae immune responses induced by a N. meningitidis vaccine (4CMenB), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04094883. (accessed 20 September 2019)."},{"key":"bibr19-2515135520923887","unstructured":"Australian New Zealand Clinical Trials Registry. ANZTR identifier ACTRN12619001478101. MenGO: does the licensed meningococcal vaccine Bexsero\u00ae provide cross-protection against gonorrhoea in gay and bisexual men? https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=376715. (accessed 31 October 2020)."},{"key":"bibr20-2515135520923887","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.4049\/jimmunol.110.5.1206","volume":"110","author":"Miller JN.","year":"1973","journal-title":"J Immunol"},{"key":"bibr21-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1203262"},{"key":"bibr22-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01589-4"},{"key":"bibr23-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.02.022"},{"key":"bibr24-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0176-0"},{"key":"bibr25-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000831"},{"key":"bibr26-2515135520923887","unstructured":"Centre for Disease Control and Prevention. The Tuskegee timeline, https:\/\/www.cdc.gov\/tuskegee\/timeline.htm. (accessed 13 August 2019)."},{"key":"bibr27-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz087"},{"key":"bibr28-2515135520923887","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00070"},{"key":"bibr29-2515135520923887","first-page":"217","volume":"412","author":"Poston TB","year":"2018","journal-title":"Curr Top Microbiol Immunol"},{"key":"bibr30-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.01.023"},{"key":"bibr31-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv137"},{"key":"bibr32-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2015.79"},{"key":"bibr33-2515135520923887","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01652"},{"key":"bibr34-2515135520923887","unstructured":"Fattom AI. Development of a nanoemulsion-based vaccine for Chlamydia infection. http:\/\/grantome.com\/grant\/NIH\/R43-AI134168-01A1. (accessed 9 September 2019)."},{"key":"bibr35-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.055"},{"key":"bibr36-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8205"},{"key":"bibr37-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.4.2005-2011.2005"},{"key":"bibr38-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20111266"},{"key":"bibr39-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.075"},{"key":"bibr40-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1435279"},{"key":"bibr41-2515135520923887","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.046128"},{"key":"bibr42-2515135520923887","unstructured":"World Health Organization. Status of vaccine research and development of vaccines for herpes simplex virus prepared for WHO PD-VAC, https:\/\/www.who.int\/immunization\/research\/meetings_workshops\/HSV_vaccineRD_Sept2014.pdf. (accessed 9 September 2019)."},{"key":"bibr43-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.4.331"},{"key":"bibr44-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.4.379"},{"key":"bibr45-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1086\/315878"},{"key":"bibr46-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.076"},{"key":"bibr47-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.03.075"},{"key":"bibr48-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix004"},{"key":"bibr49-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy415"},{"key":"bibr50-2515135520923887","first-page":"k1753","volume":"361","author":"Dyer O.","year":"2018","journal-title":"BMJ"},{"key":"bibr51-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0129-1"},{"key":"bibr52-2515135520923887","unstructured":"World Health Organization. HIV\/AIDS Summary of the global HIV epidemic 2018, https:\/\/www.who.int\/gho\/hiv\/en\/. (accessed 10 September 2019)."},{"key":"bibr53-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00110-09"},{"key":"bibr54-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908492"},{"key":"bibr55-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234150"},{"key":"bibr56-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1214785109"},{"key":"bibr57-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.17.8769-8775.2002"},{"key":"bibr58-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328363d389"},{"key":"bibr59-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT01859325. Therapeutic vaccine for HIV, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01859325. (accessed 20 March 2019)."},{"key":"bibr60-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT00056797. Therapeutic HIV vaccine and interleukin-2 to increase the immune system\u2019s response to HIV, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00056797. (accessed 20 March 2019)."},{"key":"bibr61-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT03758625. Comparison of dendritic cell-based therapeutic vaccine strategies for HIV functional cure (DC-HIV04), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03758625. (accessed 20 March 2019)."},{"key":"bibr62-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT00089531. Candidate HIV vaccine, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00089531. (accessed 20 March 2019)."},{"key":"bibr63-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT03856996. A clinical trial in healthy, HIV-1-uninfected adult participants to compare the safety, tolerability and immunogenicity of CH505TF gp120 produced from stably transfected cells to CH505TF gp120 produced from transiently transfected cells, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03856996. (accessed 20 March 2019)."},{"key":"bibr64-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT01218113. Efficacy and safety of GSK biologicals HIV vaccine in antiretroviral therapy (ART)-na\u00efve HIV-1 infected persons, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01218113. (accessed 20 March 2019)."},{"key":"bibr65-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT03606213. Therapeutic vaccination in treated HIV disease, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03606213. (accessed 20 March 2019)."},{"key":"bibr66-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT00050063. Effects of therapeutic HIV vaccination on control of HIV after discontinuation of anti-HIV drugs, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00050063. (accessed 20 March 2019)."},{"key":"bibr67-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT02972450. An HIV vaccine trial in individuals who started ART during primary or chronic infection (EHVAT01), https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02972450. (accessed 20 March 2019)."},{"key":"bibr68-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1038\/326249a0"},{"key":"bibr69-2515135520923887","unstructured":"ClinicalTrials.gov. Identifier NCT02919306. Safety and efficacy study of vaccine schedule with Ad26.Mos.HIV and MVA-Mosaic in human immunodeficiency virus (HIV)-infected adults, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02919306?term=vaccine&cond=Human+Immunodeficiency+Virus&draw=2&rank=1. (accessed 20 March 2019)."},{"key":"bibr70-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5148"},{"key":"bibr71-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30418-0"},{"key":"bibr72-2515135520923887","first-page":"0909","volume":"2011","author":"Teasdale CA","year":"2011","journal-title":"BMB Clin Evid"},{"key":"bibr73-2515135520923887","volume-title":"CDC Yellow Book 2020: Health Information for International Travel","author":"Staples JE","year":"2019"},{"key":"bibr74-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002611"},{"key":"bibr75-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711038"},{"key":"bibr76-2515135520923887","unstructured":"World Health Organization. Welcome to the WHO vaccine trial tracker, https:\/\/docs.google.com\/spreadsheets\/d\/19otvINcayJURCMg76xWO4KvuyedYbMZDcXqbyJGdcZM\/pubhtml (2019). (accessed 9 September 2020)."},{"key":"bibr77-2515135520923887","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens7030066"},{"key":"bibr78-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-017-2249-5"},{"key":"bibr79-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-019-7878-7"},{"key":"bibr80-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2867-x"},{"key":"bibr81-2515135520923887","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170773"},{"key":"bibr82-2515135520923887","first-page":"296","volume":"7","author":"Ditkowsky J","year":"2018","journal-title":"J Pediatric Infect Dis Soc"}],"container-title":["Therapeutic Advances in Vaccines and Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135520923887","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2515135520923887","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2515135520923887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T17:19:05Z","timestamp":1740935945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2515135520923887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":82,"alternative-id":["10.1177\/2515135520923887"],"URL":"https:\/\/doi.org\/10.1177\/2515135520923887","relation":{},"ISSN":["2515-1355","2515-1363"],"issn-type":[{"value":"2515-1355","type":"print"},{"value":"2515-1363","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2515135520923887"}}